Skip to content
MRD Watch

Wednesday, November 18, 2026

Subscribe
Sponsor this briefing. One site and newsletter slot, $250/week.

Briefing

The potential role of serial circulating tumor DNA (ctDNA) testing after upfront surgery to guide adjuvant chemotherapy for early stage pancreatic cancer: The AGITG DYNAMIC-Pancreas trial.

A tumor-informed approach was feasible (first draw at a median of 5 weeks). 40% were ctDNA-positive after resection, independent of usual clinicopathologic risk factors. Of 54 ctDNA-negative patients, 24 (44%) were de-escalated to a planned 3 months of adjuvant chemotherapy. Median RFS was 13 months if ctDNA-positive vs 22 months if negative (HR 0.52, P=0.003).

ASCO Annual Meeting 2024